The Federal Circuit overturned a decision by the Patent Trial and Appeal Board in Sanofi-Aventis' case against Mylan Pharmaceuticals. The Board had ruled that Sanofi-Aventis' patent claims were obvious and therefore unpatentable.
https://www.jdsupra.com/legalnews/sanofi-aventis-deutschlan-gmbh-v-mylan-2426287/
https://www.jdsupra.com/legalnews/sanofi-aventis-deutschlan-gmbh-v-mylan-2426287/